Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today reported positive interim updates from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (rGBM) and leptomeningeal metastases (LM) at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting, which took place June 24-27, 2023 in Chicago, Illinois.
Asia Mixed, Europe Markets Dip; Gold Hovers Near Record High – Global Markets Today While US Slept
Japan's Nikkei 225 declined 0.86% ending the session at 38,618.00.. Crude Oil WTI traded lower by 0.69% at $78.11/bbl, and Brent was down 0.62% at $82.36 bbl.
